Abstract

Autologous bone grafts are considered the gold standard grafting material for the treatment of nonunion, but in very large bone defects, traditional autograft alone is insufficient to induce repair. Recombinant human bone morphogenetic protein 2 (rhBMP-2) can stimulate bone regeneration and enhance the healing efficacy of bone grafts. The delivery of rhBMP-2 may even enable engineered synthetic scaffolds to be used in place of autologous bone grafts for the treatment of critical size defects, eliminating risks associated with autologous tissue harvest. We here demonstrate that an osteoinductive scaffold, fabricated by combining a 3D printed rigid polymer/ceramic composite scaffold with an rhBMP-2-eluting collagen sponge can treat extremely large-scale segmental defects in a pilot feasibility study using a new sheep metatarsus fracture model stabilized with an intramedullary nail. Bone regeneration after 24 weeks was evaluated by micro-computed tomography, mechanical testing, and histological characterization. Load-bearing cortical bridging was achieved in all animals, with increased bone volume observed in sheep that received osteoinductive scaffolds compared to sheep that received an rhBMP-2-eluting collagen sponge alone.

Highlights

  • Autologous bone grafts are considered the gold standard grafting material for the treatment of nonunion, but in very large bone defects, traditional autograft alone is insufficient to induce repair

  • We previously developed 3D printed biodegradable scaffolds made from a composite of polycaprolactone (PCL) and β-tricalcium phosphate (β-TCP) for bone regrowth

  • We designed and 3D printed a novel PCL/β-TCP scaffold with a central channel for intramedullary nail fixation and a side hook to hold and stabilize Infuse Recombinant human bone morphogenetic protein 2 (rhBMP-2) collagen sponges (Fig. 1)

Read more

Summary

Introduction

Autologous bone grafts are considered the gold standard grafting material for the treatment of nonunion, but in very large bone defects, traditional autograft alone is insufficient to induce repair. The delivery of rhBMP-2 may even enable engineered synthetic scaffolds to be used in place of autologous bone grafts for the treatment of critical size defects, eliminating risks associated with autologous tissue harvest. Autologous bone grafts generally demonstrate the greatest regenerative potential for tissue repair but are hampered by limited availability and significant complications at the donor site. Though PCL/β-TCP scaffolds provide structural support for the deposition of actively regenerating bone tissues, the ability of the scaffold material to promote new bone growth is limited. We hypothesize that incorporation of the rhBMP-2 delivery system within a rigid PCL/β-TCP scaffold may yield an engineered bone graft with greater regenerative potential than either component alone

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call